SOME RECENT PATENT APPLICATIONS IN THE AREA OF PROTEASE INHIBITORS

Patent #	Subject	Assignee	Author	Status*
WO 9618627	Tripeptide protease inhibitors for treatment of HIV infection.	Sankyo Co Ltd Tokyo, Japan	Komai T, Nakagawa A, Nishigaki T, Ozawa Y, Watanabe T, Yabe Y	6/20/96 A1
WO 9617821	Pure amino-chlorohydrin hydrochloride enantiomer. Used as intermediate for HIV protease inhibitor, avoids using hazardous chemicals and is suitable for large-scale manufacturing.	Bio-Mega/Boehringer Ingelheim Res Inc St. Joseph, MO	Beaulieu PL, Guindon Y, Wernic, D	6/13/96 A
WO 9616980	5-acylamido-4-hydroxy-alkanoyl-amido-acyl morpholino-ethylamide-aspartate protease substrates that inhibit retro-viral maturation and infectivity. Used in treatment of retroviral infections such as HIV, AIDS, ARDS, and corresponding animal retroviruses, i.e., SIV and FIV in monkeys and cats.	Ciba Geigy Ag, Basel, Switzerland	Bhagwat S, Bold G, Capraro H, Faessler A, Khanna SC, Lang M	6/6/96 A1
WO 9616050	5-hydroxy methyl thiazole is an intermediate in the preparation of HIV protease inhibitors.	Abbott Lab, Abbott Park, IL	Leanna MR, Morton HE	5/30/96 A1
US 5521219	Mimetic protease inhibitors that compete with gag and gag-pol proteins to bind to retroviral protease and inhibit the enzyme, and thus, retroviral replication—used in treating HIV, cytomegalovirus, respiratory syncitial virus, etc.	Searle & Co G D, Bucks, UK	Decrescenzo GA, Freskos JN, Getman D, Mueller RA, Talley JJ, Vazquez ML	5/28/96 A
WO 9614863	Inhibits multimeric protease via defective protease monomer that forms dysfunctional multimeric protease—used to inhibit HIV replication.	Univ California San Francisco, CA	Babe LM, Craik CS, Rose JR	5/23/96 A1
WO 9614314	Tri- and tetra- substd. thiepane compounds—used to inhibit or detect HIV protease activity, or elicit antibody response.	Gilead Sci. Inc. Foster City, CA	Bischofberger NW, Kim CU, Krawcyzk SH, Mcgee LR, Postich MJ, Yang W	5/17/96 A2
US 5514814 WO 9614296	Peptide mimetics, which can assume the conformation of . beta-pleated peptide strand of naturally occurring peptide enzyme inhibitors. They are metabolically more stable than peptides, giving increased half-life and can cross the blood/brain barrier—used in pharmaceutical, therapeutic, prophylactic and diagnostic areas.	Univ Pennsylvania, Philadelphia, PA	Hirschmann RF, Jones D, Smith AB, Sprengeler P	5/7/96 A 5/17/96 A1
WO 9612818	Biological resolution of racemic indene oxide to (1S,2R)-indene oxide, which is an intermediate for compounds useful in synthesizing inhibitors of HIV protease, renin, and other proteases—used in treatment of AIDS.	Merck & Co Inc, Whitehouse Station, NJ	Chartrain MM, Rosazza JPN, Senanayake CH, Zhang J	5/2/96 A1
WO 9612493 US 5525596	Enhancement of gastrointestinal tract absorption of zwitterionic drugs by admin. of drug in combination with palmitoyl carnitine chloride and cyclodextrin; reduces acidic and enzymatic degradation.	Merck & Co Inc Whitehouse Station NJ	Mosher GL	5/2/96 A1 6/11/96 A
WO 9612492	HIV protease inhibitors produced by biotransformation of known oligopeptide. Useful in treatment and prevention of HIV infection or AIDS, screening assays for antiviral agents, protease inhibition, etc.	Merck & Co Inc, Whitehouse Station, NJ	Arison BH, Chen S, Garrity GM, Heimbuch B, Miller RR, Shafiee A	5/2/96 A1

Source: Derwent World Patents Index, 1996. *Key: (WO) A, open for public inspection (OPI) application; A1, OPI application with international search report (from 9220); A2, OPI application without international search report (from 9220); (US) A, examined granted patent.